AQST
Aquestive Therapeutics, Inc.
NASDAQ · USHealthcareDrug Manufacturers - Specialty & Generic
$3.94-4.25%
Price as of Jul 20, 2026
AQST growth
Aquestive Therapeutics, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -7.3%
- EBITDA
- -40.6%
- EBIT
- -35.7%
- EPS
- -3.4%
- Free cash flow
- +9.6%
- Operating cash flow
- +10.1%
Forward estimates
- Revenue
- -50.3%
- EBITDA
- +70.8%
- EPS
- +52.7%
Three-year CAGR
- Revenue
- -2.2%
- EBITDA
- —
- EBIT
- —
- Net income
- -89.8%
- EPS
- -49.0%
- Free cash flow
- -47.5%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.